MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism.

[1]  M. Alcalay,et al.  Wnt Signalling in Acute Myeloid Leukaemia , 2019, Cells.

[2]  D. Zheng,et al.  Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis , 2019, Cell reports.

[3]  A. Verma,et al.  Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type , 2018, Blood.

[4]  A. Verma,et al.  Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level , 2018, Nature Medicine.

[5]  Qiang Gao,et al.  A new massively parallel nanoball sequencing platform for whole exome research , 2018, BMC Bioinformatics.

[6]  Yuan Tian,et al.  Comparative performance of the BGISEQ-500 and Illumina HiSeq4000 sequencing platforms for transcriptome analysis in plants , 2018, Plant Methods.

[7]  Jihong Sun,et al.  Casein kinase 1α: biological mechanisms and theranostic potential , 2018, Cell communication and signaling : CCS.

[8]  A. Verma,et al.  Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia , 2018, Science Translational Medicine.

[9]  M. Konopleva,et al.  Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia , 2018, Clinical Cancer Research.

[10]  Michael G. Kharas,et al.  Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation. , 2017, Cancer research.

[11]  Gary D Bader,et al.  Tracing the origins of relapse in acute myeloid leukaemia to stem cells , 2017, Nature.

[12]  M. Cobb,et al.  Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors , 2017, Science Signaling.

[13]  Chenyue W. Hu,et al.  p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status , 2017, Leukemia.

[14]  Geet Duggal,et al.  Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference , 2017, Nature Methods.

[15]  V. Pant,et al.  The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis , 2017, The Journal of pathology.

[16]  Kirby D. Johnson,et al.  p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia. , 2017, Blood.

[17]  Rashmi Kanagal-Shamanna,et al.  TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes , 2016, Cancer.

[18]  M. Boutros,et al.  Wnt signaling in cancer , 2016, Oncogene.

[19]  M. Konopleva,et al.  High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome. , 2016, Clinical lymphoma, myeloma & leukemia.

[20]  Francine E. Garrett-Bakelman,et al.  Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia , 2016, Nature Medicine.

[21]  R. Campbell,et al.  Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. , 2016, The Journal of clinical investigation.

[22]  A. Verma,et al.  Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia , 2015, Nature Medicine.

[23]  G. Boucher,et al.  The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias , 2015, Nature Genetics.

[24]  K. Riabowol,et al.  Rapid Isolation of Nuclei from Cells In Vitro. , 2015, Cold Spring Harbor protocols.

[25]  Berthold Göttgens,et al.  Functionally Distinct Subsets of Lineage-Biased Multipotent Progenitors Control Blood Production in Normal and Regenerative Conditions. , 2015, Cell stem cell.

[26]  B. Göttgens,et al.  Genome-scale definition of the transcriptional programme associated with compromised PU.1 activity in acute myeloid leukaemia , 2015, Leukemia.

[27]  B. Ko,et al.  TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution , 2015, Blood Cancer Journal.

[28]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[29]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[30]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[31]  K. Bhalla,et al.  Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells , 2014, Leukemia.

[32]  Joshua F. McMichael,et al.  Age-related cancer mutations associated with clonal hematopoietic expansion , 2014, Nature Medicine.

[33]  D. Tenen,et al.  The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells. , 2014, Blood.

[34]  J. Vera,et al.  Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target , 2014, Journal of Translational Medicine.

[35]  Michael G. Kharas,et al.  Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia , 2014, The Journal of experimental medicine.

[36]  Lincoln D. Stein,et al.  Identification of pre-leukemic hematopoietic stem cells in acute leukemia , 2014, Nature.

[37]  W. Sellers,et al.  Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974 , 2013, Proceedings of the National Academy of Sciences.

[38]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[39]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[40]  Jesper V Olsen,et al.  Systems Biology Approach Identifies the Kinase Csnk1a1 as a Regulator of the DNA Damage Response in Embryonic Stem Cells , 2013, Science Signaling.

[41]  G. Wahl,et al.  MDM2, MDMX and p53 in oncogenesis and cancer therapy , 2013, Nature Reviews Cancer.

[42]  M. Goodell,et al.  Flow cytometry analysis of murine hematopoietic stem cells , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[43]  K. Vousden,et al.  p53 mutations in cancer , 2013, Nature Cell Biology.

[44]  G. Mufti,et al.  SnapShot: Acute myeloid leukemia. , 2012, Cancer cell.

[45]  A. Becker,et al.  Casein Kinase 1α Regulates an MDMX Intramolecular Interaction To Stimulate p53 Binding , 2012, Molecular and Cellular Biology.

[46]  Mithat Gonen,et al.  Recurrent Somatic TET2 Mutations in Normal Elderly Individuals With Clonal Hematopoiesis , 2012, Nature Genetics.

[47]  C. Steidl,et al.  Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. , 2012, Blood.

[48]  I. Weissman,et al.  Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia , 2012, Science Translational Medicine.

[49]  M. Kawahara,et al.  H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. , 2012, Cancer cell.

[50]  S. Armstrong,et al.  Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. , 2012, Cell stem cell.

[51]  K. Rajewsky,et al.  Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice , 2011, Proceedings of the National Academy of Sciences.

[52]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[53]  V. Pant,et al.  Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. , 2010, Cancer research.

[54]  T. Hoang,et al.  Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. , 2010, Genes & development.

[55]  Wolfram Goessling,et al.  The Wnt/β-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML , 2010, Science.

[56]  R. Månsson,et al.  Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. , 2009, Cancer cell.

[57]  Y. Liu,et al.  p53 regulates hematopoietic stem cell quiescence. , 2009, Cell stem cell.

[58]  S. Fröhling,et al.  FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. , 2007, Cancer cell.

[59]  R. Verhaak,et al.  A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. , 2007, The Journal of clinical investigation.

[60]  R. Ren,et al.  Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. , 2007, Cancer research.

[61]  P. Pandolfi,et al.  PML-Retinoic Acid Receptor α Inhibits PML IV Enhancement of PU.1-Induced C/EBPε Expression in Myeloid Differentiation , 2007, Molecular and Cellular Biology.

[62]  L. Donehower,et al.  The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. , 2007, Blood.

[63]  Thomas Ried,et al.  Spectral karyotyping analysis of human and mouse chromosomes , 2006, Nature Protocols.

[64]  S. Reed,et al.  Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. , 2006, Journal of virological methods.

[65]  Christian Steidl,et al.  Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells , 2006, Nature Genetics.

[66]  F. Rosenbauer,et al.  Hematopoietic stem cell and multilineage defects generated by constitutive β-catenin activation , 2006, Nature Immunology.

[67]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[68]  Cornel Catana,et al.  Inhibition of protein–protein interactions: The discovery of druglike β‐catenin inhibitors by combining virtual and biophysical screening , 2006, Proteins.

[69]  T. Haferlach,et al.  Implications of NRAS mutations in AML: a study of 2502 patients. , 2006, Blood.

[70]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[71]  Yu Pan,et al.  Regulation of p53-MDMX Interaction by Casein Kinase 1 Alpha , 2005, Molecular and Cellular Biology.

[72]  J. Kutok,et al.  Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1 , 2004, Nature Genetics.

[73]  H. Macdonald,et al.  β-Catenin Is Dispensable for Hematopoiesis and Lymphopoiesis , 2004, The Journal of experimental medicine.

[74]  Thomas Ried,et al.  The Septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines. , 2003, Cancer research.

[75]  Chunaram Choudhary,et al.  Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. , 2003, Blood.

[76]  V. Rotter,et al.  TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance , 2003, Human mutation.

[77]  Daniel G. Tenen,et al.  Disruption of differentiation in human cancer: AML shows the way , 2003, Nature Reviews Cancer.

[78]  D. Gilliland,et al.  Focus on acute leukemias. , 2002, Cancer cell.

[79]  Xi He,et al.  Control of β-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism , 2002, Cell.

[80]  T. Naoe,et al.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.

[81]  I. Weissman,et al.  Identification of Clonogenic Common Lymphoid Progenitors in Mouse Bone Marrow , 1997, Cell.

[82]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[83]  R. Berger,et al.  Mutations of the P53 gene in acute myeloid leukaemia , 1992, British journal of haematology.

[84]  S. Inoue,et al.  Genomic Classification in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[85]  Lisa Garrett,et al.  Cbfβ-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia , 2006 .

[86]  D. Tenen,et al.  The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. , 2003, Blood.